Comparison of endotracheal tube and thin catheter for surfactant therapy in neonates with respiratory distress syndrome

Comparison of two methods of endotracheal tube and thin catheter for surfactant therapy in neonates with respiratory distress syndrome in NICU

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211006052685N2

Enrollment

Registered

2022-07-12

Start date

2022-01-05

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory distress syndrome. Respiratory distress syndrome of newborn

Interventions

Intervention 1: Intervention group 1: In this study, Beraksurf surfactant (Teksima Pharmaceutical Company, Iran) was used to treat newborns. The concentration of phospholipids in Beraksurf is 25 mg/ml

Eligibility

Sex/Gender

All

Age

1 Days to 30 Days

Inclusion criteria

Inclusion criteria: Infants born with a gestational age of 25 to 37 weeksA dmitted to the NICU

Exclusion criteria

Exclusion criteria: Respiratory distress due to cardiac causes hemodynamic instability sepsis and any cause other than surfactant deficiency

Design outcomes

Primary

Measure	Time frame
Treatment of respiratory distress syndrome. Timepoint: Evaluate respiratory condition of neonates at birth up to 30 days after birth. Method of measurement: Evaluate the duration and amount of need for mechanical ventilation, NCPAP and FiO2.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Rezaei

Shiraz University of Medical Sciences

md_rezaie@yahoo.co.uk+98 71 3647 4298

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026